PI3K and PTEN at the Interface of Cell Growth, Vesicular Trafficking and Disease

Web Desc
MEETING CANCELLED: PI3-Kinase and PTEN at the Interface of Cell Growth, Vesicular Trafficking and Disease
Scientific Organizers: Bart Vanhaesebroeck, Volker Haucke and Lori Friedman
Date: May 03 - 07, 2020
Location: Herrenhausen Palace, Hannover, Germany
Organized in collaboration with Volkswagen Foundation
For important information on the coronavirus, please click here
Summary of Meeting:
The Phosphoinositide 3-Kinase (PI3K) signaling pathway is a main regulator in cell growth, metabolism, and survival and Phosphatase and TENsin homolog (PTEN) is a tumor suppressor gene. This conference integrates three decades of research and development in the PI3K/PTEN field and its progression towards the understanding and treatment of human disease. The discovery of rare human disorders arising from deregulation of the PI3K/PTEN pathway is providing important insights into the organismal biology of this pathway, as well as reviving interest in the repurposing of PI3K pathway inhibitors that were originally under development as anti-cancer agents. In addition, improved strategies to effectively use PI3K inhibitors in cancer are progressing through the clinic, with exciting new opportunities to use PI3K inhibitors in cancer immunotherapy treatment. This conference will cover the mechanism of action of the phosphoinositide lipids, their turnover and their downstream effectors, especially in relation to the class II and III PI3K isoforms, whose cellular and organismal functions are gradually being uncovered. Furthermore, the program will emphasize the emerging evidence for a critical role of the PI3K/PTEN pathway in neuronal biology, immunology and autophagy. This conference brings together basic scientists, drug developers and clinicians under one venue to discuss new paradigms in the field. Thus, this conference will catalyze information exchange and spark collaborations that will foster further scientific progress toward the improvement of human health.
IT'S NOT TOO LATE TO SUBMIT YOUR ABSTRACT. Abstracts received may still be considered for a short talk if space is available. We will accept abstracts for poster acceptance until 2 weeks prior to the meeting start date.


We gratefully acknowledge additional support for this conference from:
Avanti Polar Lipids, Inc.
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

ORIC Pharmaceuticals
Keystone Symposia thanks the Volkswagen Foundation for hosting this conference:
Volkswagen Stiftung
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found